Objectives: The objective of the study was to evaluate the effect of an angiotensin receptor
blocker on left ventricular (LV) structure and function when added to prescribed heart failure …

Objectives: The objective of this study was to test the hypothesis that the severity of left
ventricular remodeling predicts the response to treatment and outcomes in chronic heart …

Background The mechanism by which angiotensin-converting enzyme inhibitors reduce
mortality rates and disease progression in patients with heart failure is likely mediated in part …

Objective: To evaluate the effect on cardiac hemodynamic parameters of valsartan in
patients with chronic stable congestive heart failure previously untreated with ACE inhibitors …

Background Sacubitril/valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF) …

Aims To investigate the effect of valsartan in the Valsartan‐Heart Failure Trial (Val‐HeFT)
when added to angiotensin‐converting enzyme inhibitor (ACEi) alone in patients with heart …

Background: To investigate the role of persistent angiotensin activity despite
angiotensinconverting enzyme inhibitor therapy in the progression of heart failure, the …

BACKGROUND In patients with heart failure, activation of the renin-angiotensin system is
common and has been postulated to provide a stimulus for further left ventricular (LV) …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Background Previous studies and case-series showed improvement in left ventricular (LV)
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …